{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:15:57Z","timestamp":1778559357836,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1124\/dmd.120.000306","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T19:43:02Z","timestamp":1614973382000},"page":"379-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Metabolic Retroversion of Piperaquine (PQ) via Hepatic Cytochrome P450\u2013Mediated N-Oxidation and Reduction: Not an Important Contributor to the Prolonged Elimination of PQ"],"prefix":"10.1016","volume":"49","author":[{"given":"Yuewu","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunrui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.120.000306_bib1","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.xphs.2018.01.009","article-title":"Inhibition of CYP3A by antimalarial piperaquine and its metabolites in human liver microsomes with IVIV extrapolation","volume":"107","author":"Aziz","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.120.000306_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/138920007779315053","article-title":"Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver","volume":"8","author":"Barter","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.120.000306_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1124\/dmd.119.089300","article-title":"N-oxygenation of oxycodone and retro-reduction of oxycodone N-oxide","volume":"48","author":"Cashman","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000306_bib4","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1128\/AAC.00366-15","article-title":"Ex vivo drug susceptibility testing and molecular profiling of clinical Plasmodium falciparum isolates from Cambodia from 2008 to 2013 suggest emerging piperaquine resistance","volume":"59","author":"Chaorattanakawee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.120.000306_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12936-020-03358-7","article-title":"Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in western Kenya","volume":"19","author":"Chebore","year":"2020","journal-title":"Malar J"},{"key":"10.1124\/dmd.120.000306_bib6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1211\/jpp.59.10.0002","article-title":"Prediction of human pharmacokinetics--gut-wall metabolism","volume":"59","author":"Fagerholm","year":"2007","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.120.000306_bib7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2174\/138920010794328931","article-title":"PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism","volume":"11","author":"Fan","year":"2010","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.120.000306_bib8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1473-3099(16)30378-4","article-title":"Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis","volume":"17","author":"Gutman","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1124\/dmd.120.000306_bib9","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.4269\/ajtmh.19-0379","article-title":"Origin and spread of evolving artemisinin-resistant Plasmodium falciparum malarial parasites in Southeast Asia","volume":"101","author":"Hassett","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"10.1124\/dmd.120.000306_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1128\/AAC.00555-07","article-title":"Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria","volume":"52","author":"Karunajeewa","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.120.000306_bib11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2165\/11203910-000000000-00000","article-title":"Dihydroartemisinin\/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria","volume":"72","author":"Keating","year":"2012","journal-title":"Drugs"},{"key":"10.1124\/dmd.120.000306_bib12","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1124\/dmd.115.063867","article-title":"Gut microbiota-mediated drug-antibiotic interactions","volume":"43","author":"Kim","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000306_bib13","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1128\/AAC.00835-15","article-title":"Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment","volume":"59","author":"Leang","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.120.000306_bib14","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3109\/00498254.2012.693972","article-title":"In vitro metabolism of piperaquine is primarily mediated by CYP3A4","volume":"42","author":"Lee","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.120.000306_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3920\/WMJ2014.1875","article-title":"Alternaria toxins of the alternariol type are not metabolised by human faecal microbiota","volume":"9","author":"Lemke","year":"2016","journal-title":"World Mycotoxin J"},{"key":"10.1124\/dmd.120.000306_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12936-017-2162-8","article-title":"A phase 1 evaluation of the pharmacokinetic\/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine","volume":"17","author":"Leong","year":"2018","journal-title":"Malar J"},{"key":"10.1124\/dmd.120.000306_bib17","doi-asserted-by":"crossref","first-page":"e3974","DOI":"10.1002\/bmc.3974","article-title":"Simultaneous determination of piperaquine and its N-oxidated metabolite in rat plasma using LC-MS\/MS","volume":"31","author":"Liu","year":"2017","journal-title":"Biomed Chromatogr"},{"key":"10.1124\/dmd.120.000306_bib18","doi-asserted-by":"crossref","first-page":"e00260","DOI":"10.1128\/AAC.00260-18","article-title":"Metabolism of piperaquine to its antiplasmodial metabolites and their pharmacokinetic profiles in healthy volunteers","volume":"62","author":"Liu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.120.000306_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12936-019-2740-z","article-title":"High cure rates and tolerability of artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Kibaha and Kigoma, Tanzania","volume":"18","author":"Mandara","year":"2019","journal-title":"Malar J"},{"key":"10.1124\/dmd.120.000306_bib20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.120.000306_bib21","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4269\/ajtmh.2008.79.620","article-title":"Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects","volume":"79","author":"Nguyen","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"10.1124\/dmd.120.000306_bib22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12936-019-2903-y","article-title":"Molecular detection of drug resistant malaria in Southern Thailand","volume":"18","author":"Noisang","year":"2019","journal-title":"Malar J"},{"key":"10.1124\/dmd.120.000306_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10928-010-9185-x","article-title":"Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion","volume":"37","author":"Pang","year":"2010","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/dmd.120.000306_bib24","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1211\/jpp.60.10.0001","article-title":"Formed and preformed metabolites: facts and comparisons","volume":"60","author":"Pang","year":"2008","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.120.000306_bib25","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1124\/dmd.104.000802","article-title":"Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin","volume":"33","author":"Parte","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000306_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/jiw128","article-title":"Piperaquine monotherapy of drug-susceptible Plasmodium falciparum infection results in rapid clearance of parasitemia but is followed by the appearance of gametocytemia","volume":"214","author":"Pasay","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1124\/dmd.120.000306_bib27","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1016\/j.xphs.2019.08.004","article-title":"Applying two orthogonal methods to assess accuracy of plasma protein binding measurements for highly bound compounds","volume":"108","author":"Ryu","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.120.000306_bib28","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1124\/dmd.116.072363","article-title":"Stereoselective metabolism of bupropion to OH-bupropion, threohydrobupropion, erythrohydrobupropion, and 4\u2032-OH-bupropion in vitro","volume":"44","author":"Sager","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000306_bib29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1080\/00498254.2019.1664791","article-title":"Predicting successful\/unsuccessful extrapolation for in vivo total clearance of model compounds with a variety of hepatic intrinsic metabolism and protein bindings in humans from pharmacokinetic data using chimeric mice with humanised liver","volume":"50","author":"Sawada","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.120.000306_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0169-409X(97)00039-2","article-title":"Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction","volume":"27","author":"Shen","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.120.000306_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1248\/bpb.35.413","article-title":"Identification of enzymes responsible for the N-oxidation of darexaban glucuronide, the pharmacologically active metabolite of darexaban, and the glucuronidation of darexaban N-oxides in human liver microsomes","volume":"35","author":"Shiraga","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.120.000306_bib32","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/dmd.109.029959","volume":"38","author":"Sun","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000306_bib33","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1124\/dmd.106.011494","article-title":"Characterization of human urinary metabolites of the antimalarial piperaquine","volume":"34","author":"Tarning","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000306_bib34","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1128\/AAC.49.12.5127-5128.2005","article-title":"Pitfalls in estimating piperaquine elimination","volume":"49","author":"Tarning","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.120.000306_bib35","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1002\/jps.21226","article-title":"Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat","volume":"97","author":"Tarning","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.120.000306_bib36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12936-015-0600-z","article-title":"Drying anti-malarial drugs in vitro tests to outsource SYBR green assays","volume":"14","author":"Traore","year":"2015","journal-title":"Malar J"},{"key":"10.1124\/dmd.120.000306_bib37","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpba.2015.11.016","article-title":"Metabolism of dictamnine in liver microsomes from mouse, rat, dog, monkey, and human","volume":"119","author":"Wang","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.120.000306_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12936-019-2864-1","article-title":"High therapeutic efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Somalia","volume":"18","author":"Warsame","year":"2019","journal-title":"Malar J"},{"key":"10.1124\/dmd.120.000306_bib39","series-title":"Guidelines for the Treatment of Malaria","year":"2015"},{"key":"10.1124\/dmd.120.000306_bib40","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1124\/dmd.112.045765","article-title":"Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes","volume":"40","author":"Xing","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000306_bib41","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/bmc.3689","article-title":"Metabolite identification of the antimalarial piperaquine in vivo using liquid chromatography-high-resolution mass spectrometry in combination with multiple data-mining tools in tandem","volume":"30","author":"Yang","year":"2016","journal-title":"Biomed Chromatogr"},{"key":"10.1124\/dmd.120.000306_bib42","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1124\/dmd.115.064386","article-title":"Intestinal absorption and metabolism of epimedium flavonoids in osteoporosis rats","volume":"43","author":"Zhou","year":"2015","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.120.000306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:50:10Z","timestamp":1740055810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624079595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0090955624079595"],"URL":"https:\/\/doi.org\/10.1124\/dmd.120.000306","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic Retroversion of Piperaquine (PQ) via Hepatic Cytochrome P450\u2013Mediated N-Oxidation and Reduction: Not an Important Contributor to the Prolonged Elimination of PQ","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.120.000306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}